NASDAQ$AUPH

Aurinia Pharmaceuticals Inc. · Q4 2024 earnings

Q4 2024 earnings · · Before market open · Investor relations

Briefing

AUPH reported Q4 2024 revenue of $59.9M, net income of $1.4M.

For Q4 2024, AUPH reported Revenue was $59.9M, net income was $1.4M. Management discusses operating trends, liquidity, and outlook in the filing.

  • Revenue $59.9M for Q4 2024.
  • Net income $1.4M.
  • MD&A highlights operating priorities, liquidity, and sector risks.

Headline financials

Total Revenue

$59.9M

Previous: $45.1M+32.8%
EPS (adj)

$0.01

Previous: -$0.19+105.3%
Operating Cash Flow

$30.1M

No prior period
Net Income

$1.4M

Previous: -$26.9M+105.2%

Revenue & EPS history

Aurinia · Revenue · Quarterly

$59.9M

Q4 2024+32.8%vs Q4 2023
Beat estimate in 15 of 15 quarters(100%)
ActualEstimate

Revenue by segment

Aurinia · $40.8M total across 1 segment · Q3 2023

  • Net Product Sales
    $40.8M+59.9%

Forward guidance

The filing discusses operating priorities, capital allocation, and demand trends.

Tailwinds

  • Management outlines strategic priorities and cost actions.
  • Segment commentary supports the earnings narrative.

Headwinds

  • Macro, rates, or input costs may pressure margins.
  • One-time items can affect year-over-year comparability.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2024

Historical avgQ4 2024

-1.4%

Avg return

Earnings day

-0.3%

Avg return

5 days after

+4.6%

Avg return

30 days after

41%

18 / 44 earnings

Positive

+25.7%

Q2 2021

Best reaction

-32.3%

Q3 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-7.0%-1.6%-2.6%
Q4 2025-3.1%-1.9%-1.1%
Q3 2025-3.4%+8.5%+8.1%
Q1 2025+1.8%+2.4%+1.1%
Q4 2024-5.0%+1.6%+4.3%
Q3 2024+10.6%+11.4%+18.8%
Q2 2024-6.5%-4.4%+15.8%
Q1 2024-1.9%-1.5%+4.2%
Q4 2023-26.6%-29.9%-35.1%
Q3 2023+15.4%+16.3%+27.1%
Q2 2023-3.1%-4.1%-6.6%
Q1 2023-1.1%-4.2%-18.4%
Q4 2022+7.9%+7.9%+31.8%
Q3 2022-32.3%-29.3%-33.0%
Q2 2022-1.5%-4.4%-15.1%
Q1 2022+7.1%+24.9%+35.2%
Q4 2021-26.0%-34.9%-23.7%
Q3 2021-0.3%-2.1%-41.7%
Q2 2021+25.7%+32.9%+52.9%
Q1 2021-17.3%-8.5%+1.7%
Q4 2020+1.4%+0.7%-12.9%
Q3 2020-4.0%-3.1%+7.3%
Q2 2020-1.3%-2.4%-0.8%
Q1 2020-2.3%-3.7%-11.7%
Q4 2019-9.0%-16.9%-22.1%
Q3 2019-2.4%+13.6%+245.4%
Q2 2019-7.5%-7.5%-6.4%
Q1 2019+4.3%+8.9%+3.6%
Q4 2018+8.9%+3.2%+0.6%
Q3 2018+1.3%-6.5%+9.7%
Q2 2018+0.4%-0.9%+0.4%
Q1 2018+7.3%+20.3%+5.7%
Q4 2017+6.5%+0.8%+1.5%
Q3 2017-11.0%-8.5%-15.3%
Q2 2017+1.7%+4.4%+13.3%
Q1 2017-4.6%-6.6%-22.3%
Q4 2016+18.7%-1.5%-11.0%
Q3 2016+1.2%-0.8%+13.3%
Q2 2016+4.9%+17.7%-41.4%
Q1 2016
Q4 2015+0.0%
Q3 2015-4.8%
Q2 2015-4.0%
Q4 2014+4.9%
Q3 2014-7.2%
Q2 2014
Q1 2014
Q4 2013
Q3 2013
Q2 2013
Q1 2013
Q4 2012
Q3 2012
Q2 2012
Q1 2012
Q4 2011
Q3 2011
Q2 2011
Q1 2011
Q4 2010
Q3 2010
Q2 2010
Q1 2010

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro